Amphastar Q2 GAAP net income slips 2.2% to $30.35 million; revenue rises 5.4% to $183.9 million
AMPH•Q2 revenue and earnings
Amphastar posted Q2 net revenues of $183.9 million, up 5% from a year earlier.
GAAP net income slipped to $30.3 million; GAAP diluted EPS rose to $0.67.
Adjusted non-GAAP net income was $40.8 million; adjusted non-GAAP diluted EPS increased to $0.91.
Margins and product sales
Gross margin widened to 50.8% from 49.6% on higher sales of recently launched, higher-margin products.
BAQSIMI annual net sales hit a $175 million milestone, triggering a $100 million payment due in Q3; ipratropium bromide added $8.4 million after an April launch.
